MAM
Hot Star takes to cinema advertising to reach younger TG : Feb ’15 CAM report
MUMBAI: Being the newest entrant on the bloc, Star India’s digital baby Hot Star has managed to create the necessary buzz around it. The digital app, in a bid to reach a wider segment of young audiences, has chosen cinema advertising as part of its mega marketing campaign.
Using the movie Roy as a case study, the CAM report for the month of February 2015 found that out of the 200 screens, they were present in 32 per cent of the screens, which is close to 65 screens. “This number is more than the category that four wheeler and mobile phones undertake for their campaigns,” said Interactive Television CEO Ajay Mehta.
According to industry experts and estimates, Hot Star undertook cinema advertising because of the demographics to reach out effectively to their TG i.e young audiences. The campaign for cinema advertising undertaken across the eight metros could have cost Star India close to Rs 50 – 70 lakhs. Such campaigns are usually undertaken for a period of four weeks. In the past, apps such as Free Charge, Viber and Hike have used cinema advertising extensively in similar patterns.
The report also found that during the same period, a total of 297 brands were active. Banking and Finance have emerged as the top category spending with State Bank of India topping the list. F&B followed with beauty and Personal care coming third in the hierarchy.
“There has been a three per cent increase in the number of brands active on cinema with the movie Roy in February 2015 round as compared to the earlier round,” adds Mehta.
There has also been a major increase in spending of clothing/apparels category from 45 per cent in January 2015 to 79 per cent in February 2015. The automobile category has increased from 34 per cent to 57 per cent during the same period. Online portals too increased their spending from 21 per cent to 48 per cent for the same period. Choc On has the highest recall with 24 per cent present in 152 screens followed by Syska LED with 20 per cent present in 136 screens.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
